IP Library Granted Patent US 7,741,321
Granted Patent B2
US 7,741,321 · App. 11/594,431 · Granted Jun 22, 2010

Modulators of ATP-binding cassette transporters

Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,741,321
App. No.
11/594,431
Granted
Jun 22, 2010
Kind
B2
Abstract

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Claims (19)

1. A kit for use in measuring the activity of CFTR in a biological sample in vitro or in vivo, comprising:

(i) a compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

Each R 1 is an optionally substituted C 1-6 aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3-10 cycloaliphatic, an optionally substituted 3 to 10 membered heterocycloaliphatic, carboxy, amido, amino, halo, or hydroxy, provided that at least one R 1 is an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl attached to the 5- or 6- position of the pyridyl ring;

Each R 2 is hydrogen, an optionally substituted C 1-6 aliphatic, an optionally substituted C 3-6 cycloaliphatic, an optionally substituted phenyl, or an optionally substituted heteroaryl;

Each R 3 and R′ 3 together with the carbon atom to which they are attached form an optionally substituted C 3-7 cycloaliphatic or an optionally substituted heterocycloaliphatic;

Each R 4 is an optionally substituted aryl or an optionally substituted heteroaryl; and

Each n is 1,2,3 or 4; and

(ii) instructions for:

a) contacting the compound with the biological sample; and

b) measuring activity of said CFTR.

2. The kit according to claim 1 , further comprising instructions for

a) contacting an additional compound with the biological sample;

b) measuring the activity of said CFTR in the presence of said additional compound, and

c) comparing the activity of the CFTR in the presence of the additional compound with the activity of the CFTR in the presence of a compound of formula (I).

3. The kit according to claim 1 wherein the compound of formula (I) is selected from

4. The kit of claim 1 , 2 or 3 , wherein the CFTR is ΔF508 CFTR.

5. The kit of claim 1 , 2 or 3 , wherein the CFTR is G551D CFTR.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 1, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037676/0031 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2007
From: HADIDA RUAH, SARA S.; HAMILSON, MATTHEW; MILLER, MARK; GROOTENHUIS, PETER D.J.; BEAR, BRIAN; MCCARTNEY, JASON; ZHOU, JINGLAN
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 018920/0717 →
Continuity (4)
Provisional Application 6073450600 · Nov 8, 2005
Provisional Application 6075408600 · Dec 27, 2005
Provisional Application 6080245800 · May 22, 2006
Related Publication 20080113985A1 · May 15, 2008